State of the art - how I manage coagulopathy in cardiac surgery patients

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Over 35,000 cardiopulmonary bypass surgeries occur annually in the UK, with significant post-operative bleeding affecting morbidity.
• Allogeneic blood product usage can reach 50%, highlighting the need for effective bleeding management strategies.

Purpose of the Study:

• To review preventative measures for reducing post-operative bleeding in cardiac surgery.
• To evaluate the current management of bleeding using factor concentrates and the evidence supporting their use.

Main Methods:

• Review of recent publications and clinical trials concerning post-operative bleeding in cardiac surgery.
• Analysis of the efficacy and supporting evidence for various factor concentrates (e.g., prothrombin complex, fibrinogen, factor XIII, factor IX).

Main Results:

• Despite improved surgical techniques, significant post-operative blood loss persists.
• Fresh frozen plasma is often inadequate; off-label use of specific factor concentrates is increasing.
• Recent trials with factor XIII and IX concentrates have shown limited success.

Conclusions:

• There is a need for better strategies to manage and prevent post-operative bleeding after cardiac surgery.
• The widespread use of certain factor concentrates is not well-supported by robust evidence.
• Further research is required to establish optimal treatment protocols for coagulopathy in this setting.